Atlanta, Georgia — Researchers are exploring whether flickering lights and sound can help slow the progression of Alzheimer’s disease, a condition that affects millions of older Americans. Annabelle Singer, a biomedical engineer at the Georgia Institute of Technology and Emory University, is leading the charge in this innovative approach to understanding the brain’s neural patterns in patients suffering from memory impairments associated with Alzheimer’s.
In her lab, Singer is focused on deciphering what goes wrong in the brain’s electrical activity as the disease progresses. Rather than following traditional pharmaceutical routes, she is experimenting with non-invasive sensory stimulation techniques. Her distinctive method employs goggles that emit rapid flickering lights combined with beeping sounds. This setup allows her to investigate how sensory input impacts memory functions in Alzheimer’s patients by stimulating the areas of the brain responsible for memory retention.
Singer’s initial findings are promising. Preliminary studies have indicated that daily exposure to this 40 Hz light and sound stimulation could effectively slow down cognitive decline and prevent volume loss in brain regions critical for memory. “This is not about reversing existing impairments; our goal is to decelerate the ongoing decline,” she explained.
The scale of the problem is significant, with over 7 million Americans aged 65 and older currently diagnosed with Alzheimer’s. This number is projected to reach 13.8 million by 2060 if no effective treatments are discovered. Globally, Alzheimer’s is the most prevalent form of dementia among roughly 57 million individuals, highlighting the urgency for new therapeutic options.
While considerable investment has been directed toward pharmaceutical treatments, criticisms surround their safety and efficacy. New drugs such as lecanemab and donanemab offer only slight improvements and come with potentially severe side effects, raising questions about their overall value. The high costs associated with these therapies further limit accessibility for many patients.
In an effort to challenge the conventional approach, a Phase 3 clinical trial is currently underway, involving nearly 700 participants across 70 locations in the U.S. The study is organized by Cognito Therapeutics, a company specializing in wearable technologies. Singer serves as a scientific advisor on their board, supporting research aimed at determining whether cognitive decline can be moderated through her unique stimulation methods.
Years of research have reinforced the belief that light and sound can impact brain activity. Collaborating with James Lah, director of the Cognitive Neurology Program at Emory University, Singer previously conducted proof-of-concept studies on this dual-stimulation approach. Their initial trial demonstrated significant electrical connectivity changes in the brain of participants after just eight weeks of treatment, paving the way for the larger trial.
Singer’s background in theater, where she was captivated by the combination of lights and sound, has influenced her unique methodological approach. As a child, she initially dreamed of set design, never envisioning that her fascination would lead her to biomedical engineering. Yet, her passion for sensory experiences has informed her research, driving her quest to find new ways to address the challenges posed by Alzheimer’s.
The possibility of a low-risk, easily accessible intervention excites Singer as she stresses the importance of exploring every avenue in treatment possibilities. As the clinical trial progresses, researchers remain hopeful for results that could shift the paradigm of Alzheimer’s care.
Lah underscored the significance of this line of inquiry, expressing enthusiasm about the potential implications of external stimulation for modifying brain activity. “It’s a fascinating field,” he remarked, emphasizing the innovative nature of the research.
While time will ultimately reveal the effectiveness of this approach, Singer’s dedication to enhancing the lives of those affected by Alzheimer’s is clear, illustrating a pathway for both scientific inquiry and compassionate care in a rapidly aging world.